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The Monsanto Equation: Is Bayer’s acquisition plan adding up? 
On a spring day on 23rd March 2016, Werner Baumann, who had just become CEO of Bayer 
AG 23 days earlier, sent out a letter comprising of what could become the largest acquisition 
ever done in the history of German companies. He had just released Bayer’s all-cash offer to 
acquire Monsanto for a total price of $62bn to create a global leader in the agrochemical 
business. While Monsanto is by far the world’s largest player in the seed business with 36% 
global market share in 2015 and particularly successful in the American market, Bayer is 
leading in several areas of the crop protection market with 18% market share and main focus 
in Europe. With the transaction completed, a mega player in the industry would emerge which 
could easily dwarf its remaining competitors.  
About half a year and a lengthy bidding process later, the Monsanto Board of Directors finally 
agreed upon Bayer’s all-cash offer of $128 per share which values the company at $66bn. What 
was striking, however, was that after the day of the announcement, Monsanto’s share price 
dropped almost 5% to $101.08 instead of rising closer to the agreed upon takeover price as 
empirical evidence shows in takeover scenarios (Berk & DeMarzo, 2014). 
General overview of the Agrochemical Industry 
Generally, the agrochemical industry can be sub-divided into the two clusters crop protection 
(herbicides, fungicides, etc.) and seed business. While most companies engage in both 
categories, in terms of annual sales in 2015, Syngenta is with $10bn industry leading in the first 
and Monsanto with $10.2bn in the second category. 
In 2015, global sales of crop chemicals, excluding seed businesses, summed up to $50bn with 
North and South America representing the largest market with a share of 45%, followed by Asia 
in the second place with 24%, and Europe in third with a 15% share (Exhibit 1). Global sales 
of seeds added another $29bn in sales to the agrochemical industry.  
Over the last years, the most distinctive characteristic of the agrochemical industry has been the 
lack of growth opportunities and the thus resulting considerable degree of M&A activities. 
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Growth in this industry is mainly driven by an increasing demand for food due to rising 
population, changing diets and the scarcity of land available for cultivation, as well as an 
increasing awareness of the benefits of crop protection methods. Next to these macro drivers, 
there are several micro factors that influence the crop protection and seed business. These range 
from weather conditions such as droughts or floods to crop prices as well as available acreage 
which play a significant role in farmers’ spending.  
From 1961 to 2011, the number of people supported by one hectare land rose from 2.2 to 5. 
While in this period population grew by 130%, arable land only increased by 9% which 
highlights a clear demand for a more efficient cultivation system. The world population is 
expected to grow another 30% by 2050, indicating still a substantial growth however at a 
reduced pace (Bloomberg, 2016). 
In terms of structure, the industry is led by a few big players of which, in 2015, the three largest 
companies with respect to sales were responsible for around 50% of total sales worldwide ( 
Exhibit 2).  
As the recent M&A wave implies, the agrochemical business is facing several challenges. Sales 
in the industry have begun slowing down already in the 1980s. Furthermore, in 2016, corn and 
soybean prices have declined for the third succeeding year as a result of healthy crops and 
strong harvests especially in the Americas (Phillips McDougall , 2015). Consequently, farmer’s 
spending ability has declined and more and more customers moved to generic products. This, 
as well as heavy price pressure from competitors, had a depressing effect on glyphosate1 prices, 
which is one of the main and most relevant agrochemical products, especially for Monsanto. 
Headwind is also expected from depreciating currencies in key markets such as Brazil and 
Argentina. 
Furthermore, particularly in the North and South American market, another new challenge has 
                                                 
1 Glyphosate is one of the most widely used broad-spectrum herbicides around the globe killing weeds and 
grasses that compete with crops.  
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emerged due to an increasing number of glyphosate-tolerant weeds and grasses as a result of 
the constant reapplication of one and the same product over the years (Phillips McDougall , 
2015).  
These factors and the lack of growth opportunities in the agrochemical industry have led to a 
significant amount of company consolidation in the previous decade. The most recent and 
prominent ones to mention have been the $130bn merger of DuPont and Dow Chemical, as 
respectively 4th and 6th largest agrochemical companies in the world in terms of sales, as well 
as the recent $43bn acquisition of industry leader Syngenta by ChemChina (Fontanella-Khan 
& Massoudi, 2016).  
The Players 
After the two M&A announcements of ChemChina and Syngenta as well as Dow and DuPont, 
the industry was left with three major players still to react: BASF, Bayer and Monsanto. With 
this shift in the competitive landscape of the industry, the remaining three companies found 
themselves in a difficult situation: The player who is making the last move and is likely to stand 
alone in the market will possibly lose its importance in the market due to comparative 
disadvantage in terms of market share and immense margin pressure due to the sheer size of the 
other competitors.  
BASF 
Headquartered in Ludwigshafen, the German company BASF is the largest chemical company 
in the world in terms of sales with around €70bn in 2015 (BASF, 2015). Its portfolio is 
diversified into the five sectors Oil & Gas, Chemicals, Performance Products, Functional 
Materials and Agricultural Solutions. Overall, in 2015, BASF’s agricultural division makes up 
9% of the company’s portfolio in terms of sales, however 17% in terms of EBIT (BASF, 2015). 
In the global market for crop protection, the company ranks 3rd in terms of sales among its 
competitors.  
BASF’s agricultural business mainly focuses on crop protection and even though the company 
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operates research facilities for genetically modified products as well, there is currently no 
revenue generated from any kind of seed business. The company strongly focuses on fungicides 
and herbicides with 43% and 37% respectively in terms of overall crop protection sales. The 
remaining 20% are a result of insecticide operations and functional crop care (biological crop 
protection, seed treatment etc.) (BASF, 2015).  
In the past two years, the company has been struggling as a result of depressed oil prices. In 
2015, BASF’s Chemical as well as Oil & Gas segment, which make up 49% of the total 
EBITDA, have recorded substantial losses and suffered from a 14% decrease in sales, while the 
Agrochemicals on the other hand increased by almost 7%. Expanding the agro sector would 
make strategic sense for BASF in order to balance the dependency on global oil prices. The 
company has allegedly been working on a takeover bid for Syngenta before the ChemChina 
acquisition announcement. Due to investor’s expectations for the company to make a move, 
and as BASF also has a long history of close collaboration with Monsanto, it has been rumored 
that the company’s board of directors evaluates a potential acquisition offer.  
Bayer  
The Leverkusen-based company with annual sales of €47bn in 2015 was initially focused on 
the chemicals sector, but is known today as major pharmaceutical company. In 2014, the 
company then decided to exclusively focus on its LifeScience business by spinning off its 
MaterialScience unit into a separate company which today operates and trades under the name 
Covestro (Phillips McDougall , 2015). By focusing their operations on LifeSciences, Bayer 
diversified its portfolio into the non-cyclical, high-risk pharmaceutical business as well as in 
the very cyclical, low-risk agricultural business. 
Besides the crop protection business, Bayer’s CropScience unit includes an Environmental 
Science unit as well as a seed and Genomics business. As of now, the latter only represents a 
small share of Bayer’s CropScience activities. However, the company has taken several 
strategic moves in the last years intending to strengthen and realigning its seed business 
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(Phillips McDougall , 2015).  
For Bayer, the Monsanto integration would not only mean that they could create a global leader 
in the agrochemical industry, but also narrow the gap between them and their major German 
rival BASF in terms of sales and profitability.  
Monsanto  
The St.-Louis based Monsanto is a multinational agrochemical company with main focus in the 
plant biotechnology sector and annual sales of $15bn in 2015. The company can be divided into 
the two sectors Seeds and Genomics as well as Agricultural Productivity (crop protection), 
which respectively make up 74% and 26% of total sales in 2015 (Exhibit 5.7) (Monsanto, 2015). 
The invention and the market development of the non-selective herbicide glyphosate, which is 
marketed under the name Roundup, resulted in major economic benefits for the company. In 
the 1980s, Monsanto started to invest into its seed business which led to an extensive product 
portfolio of glyphosate tolerant and/or insect resistant crops, which are marketed as Roundup 
Ready (Phillips McDougall , 2015).  
In the past years, Monsanto’s performance has been struggling due to a fourth straight annual 
decline in U.S. farmers’ incomes, the immense depreciation of Brazilian real as well as an 
increase in competition (Exhibit 5.3 & 5.4) (Prella & Minder, 2016). In 2000, Monsanto lost its 
remaining outstanding glyphosate patents which in turn resulted in an increased amount of 
producers. This ultimately led to oversupply in the market and margin decline due to the 
introduction of generic products.  
In their Seeds and Genomics business, however, Monsanto is still leading in the market and 
benefits from a long history of successful R&D. An example for this is the trait 
DroughtGuardTM which is the world’s only drought-tolerant corn seed (Monsanto , 2017). This 
is a particular advantage in terms of sales when weather phenomena such as La Niña which are 
expected to bring droughts to South America in 2017 (Sullivan, 2016). 
The company expects a growth in its soy bean business of 20% in the upcoming year as a result 
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of its newly launched Intacta RR2Pro and Roundup Ready 2 Xtend soybeans which both 
experienced rapid growth in FY 2016 (Monsanto, 2016). Overall revenue however still faces 
some headwind as a result of depressed farmers spending as well as continuing depreciating 
currencies in key markets. According to the U.S. Department of Agriculture, crop prices are 
expected to continue to decline until the end of 2016, then slowly picking up again in 2017 until 
2020 (Exhibit 5.4) (USDA, 2016).  
Deal Timeline 
After rumors emerged on 19th May 2016 that BASF as well as Bayer were interested in 
acquiring Monsanto, the market reacted by a substantial decline of 5% of the Bayer share, an 
almost 11% increase in the Monsanto share while barely showing any movement of the BASF 
share, indicating that a takeover scenario by Bayer seems most probable (Exhibit 7.2) .   
May 16 Bayer offers to acquire Monsanto to create a global leader in agrochemicals for $122 per  
 share all-cash offer, valuing Monsanto at $63bn on 23rd May. Monsanto announces openness 
 to deal however rejects offer as inadequate. Additional clarification on financing and 
 regulatory matters are required. 
Jul 16 Bayer increased all-cash offer to $125 per share, representing a 40% premium from 
Monsanto’s closing price before the first rumors emerged. 
Jul 16 Monsanto repeatedly rejects offer from Bayer as financially inadequate. 
Aug 16 Bayer reviews Monsanto’s financial accounts to justify a revised offer with a raised bid. 
Option for hostile takeover has not been ruled out. 
Sep 16 Bayer revises offer to $127.50 per Monsanto share. Bid is still below the hurdle of $149 a 
share needed to match the EV/EBITDA multiple that ChemChina is paying for Syngenta. 
Sep 16 Bayer revises offer to $128 per Monsanto share valuing the company at $66bn including net 
debt. This represents a 44% premium of Monsanto’s share price one day before the offer 
announcement and values the company’s equity at $57bn. Monsanto’s board of directors 
accepts the offer. Bayer expects around $1.5bn annual synergies after year three. 
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Benefits of the Deal 
Bayer CEO Werner Baumann (2016) believes in five major benefits of the deal.  
First of all, the assimilation of Monsanto would balance Bayer’s overall product portfolio from 
a 70/30 healthcare to crop science ratio to approximately 50/50.  
Second, the agrochemical sector offers Bayer an attractive low risk industry that is benefitting 
from inevitable macro trends such as the population growth and consequently the immense 
increase in the number of people that need to be supplied per hectare of land.  
Third, in terms of global sales among industry leaders the combined companies would by far 
be leading with projected 30% higher sales than any of its competitors.  
Fourth, Bayer’s and Monsanto’s product portfolios are almost ideally for a merger scenario. 
Instead of creating a monopoly in a certain sector, in which case the transaction would most 
certainly be blocked by anti-trust agencies, the two companies align with only very little overlap. 
The few existing overlays, especially in the herbicide sector, could be divested in order for the 
deal to go through. With this acquisition, Bayer expands and diversifies its agribusiness in all 
areas of the crop chemicals market, including crop protection, seed business as well as digital 
farming.  
Last but not least, the timing of the deal plays an important role. With the recent rapid market 
consolidation in the agrochemical world, Bayer has been under pressure to make a move in 
order to stay competitive in the market. As Bayer has obliterated all its chemical operations 
except for its LifeScience division, the company is much more dependent on a profitable 
agribusiness than its more diversified competitors.  
Challenges of the Deal 
Antitrust regulations 
All mergers and acquisitions have to be approved by regulators in order to prevent the creation 
of monopolies that could threat the competition in the market. Theoretically, takeovers need to 
be approved by more than 80 jurisdictions worldwide (DeMarzo & Berk, 2014). Practically, 
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however, the most important jurisdictions are Europe and the United Sates. Owing to the vast 
impact on the countries and Monsanto’s market share, also the authorities in Brazil and China 
are not to be neglected in this deal (Lynch & Cazan, 2016). Before the actual acquisition can 
occur, Bayer needs to have government approval by these authorities (DeMarzo & Berk, 2014). 
Due to the substantial size and market share of the two companies, the regulatory approval of 
the deal sows seeds of doubt among investors. As a consequence, instead of rising, Monsanto’s 
share price fell by almost 6% after the acquisition agreement in September 2016.  
In 2007, Monsanto intended to acquire the large cotton seed producer Delta & Pine Land 
Company. The acquisition has been refused by US antitrust authorities until Monsanto divested 
the Stoneville Pedigreed Seed Company, which is a similar enterprise. The buying party at the 
time happened to be no other than Bayer. Nine years later investors wonder whether the 
Monsanto-Stoneville reunion could pose a potential threat on the completion of the deal (Lynch 
& Cazan, 2016). 
Ever since however, the agrochemical industry underwent several changes of which most 
notably has been the consolidation of some of the largest players, reducing the amount of six 
major players into three or four.  
While Bayer is big in crop protection and the European market, Monsanto focuses on seeds and 
related biotechnology mainly in the American market (Fehler! Verweisquelle konnte nicht 
gefunden werden.). For this reason, Bayer executives argue that overlaps between the two 
companies are minimal and that concerns were resolvable with divestures (Exhibit 4). 
Furthermore, Bayer promised to pay a break-up fee of $2bn in case the deal gets rejected due 
to anti-trust reasons (Bayer, 2016).  
Monsanto’s image 
For more than two decades, Monsanto has been the number 1 producer of seeds and 
biotechnology traits that help farmers control unforeseen environmental factors that could 
damage crop yields. The company’s heavy engagement in genetically modified seeds and crop 
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protection chemicals made the company the main target for activists who claim Monsanto’s 
products pose a serious threat to the human health as well as on the natural evolution process 
of plants. On top of that, Monsanto has been blamed amongst others for legal tactics used to 
file for patents, suicides of farmers as well as for the decline of certain species such as the 
monarch butterfly (Skerritt, 2016). 
Even though the company rejected the criticism and none of the studies could prove any health 
risk of genetically engineered crops as well as Monsanto’s glyphosate, the company’s reputation 
maintained its bad image (Serafino & Kirchfeld, 2016). In 2015, Monsanto got ranked by the 
Harris Poll’s as the 4th most hated company in the U.S., ranked worse than BP (No. 11) and 
Halliburton (No. 5) who have been involved in the Deepwater Horizon Oil Spill (Otani, 2015).  
Bayer’s current CEO, Werner Baumann, is confident that this bad image vanishes after the 
merger has been completed. In an interview (2016) he said that “Bayer’s name and Bayer’s 
reputation stands for science, innovation and an utmost level of responsibility for societal needs, 
and that is what we are going to leverage on, also for the combined company going forward.” 
The idea is, as Bayer has done in previous mergers, to erase Monsanto’s brand name with the 
completion of the deal (Baumann, 2016). Besides, other companies in the seed business such 
as Bayer itself do not seem to be in the crossfire of negative publicity. Bayer actually seems to 
be quite the contrary to Monsanto as it enjoys a great reputation among the general public as it 
has just been voted as one of America’s most reputable companies (Bayer, 2015). 
Financing 
To complete the deal as soon as possible, Bayer secured a bridge financing for $57bn initially 
committed by five major banks, before being distributed to a larger syndicate. For the 
permanent financing, Bayer announced to employ a combination of debt and equity. The 
planned equity component amounts to $19bn which will be raised with the help of $4bn 
mandatory convertible bonds (issued on 11/09/16) as well as through a rights issue. With this 
planned equity issuance and current EUR/USD exchange rate, Bayer stays within the previously 
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granted authorized capital (Exhibit 9) (Authorized Capital, §§ 202-206 AktG). This was a 
strategic move by Bayer in order to avoid a shareholder’s vote. This would, according to the 
German law, require a majority of 75% of the shareholders voting in favor of the transaction 
(Bayer , 2015). Due to Monsanto’s image and a large amount of activist investors, this vote 
could have caused a serious threat for the transaction. 
In addition, the low interest rate environment and Bayer’s creditworthiness (long-term rating: 
Moody’s A3, S&P A-) are also beneficial and enable a large amount of debt financing.  
On the contrary, Bayer’s current market cap sums up to $81bn and issuing $38bn of debt plus 
adding Monsanto’s indebtedness will change the financial risk profile of the company. 
Moreover, also Monsanto’s balance sheet records a high amount of net debt due to a recent 
$10bn share repurchasing program. All three major rating agencies (Moody’s, S&P, Fitch) have 
announced to likely downgrade Bayer one or two notches in case the transaction goes through.  
Conclusion 
Looking at the market reaction after the announcement of the deal and the lack of trust of 
investors that the deal will actually go through, Baumann was wondering whether this has 
actually been the right strategic move to make. He was thinking to himself whether the bidding 
process and the ultimate price for Monsanto were too aggressive due to the fear that BASF 
could have made the move. Will Bayer even be able to raise enough money to finance the 
transaction? How can we convince our shareholders to provide us with the necessary increase 
in equity and how would this affect our stock price?  
More profoundly, was this the right decision to make given the current situation of the market 
or would there have been alternatives that we didn’t consider? How will our competition react? 
Was the timing right to enter into this agreement? With all the other M&A activities and the low 
interest rate environment, acquisition premiums may be quite considerable. What other risks 
have not been considered yet? All these challenges will impose a substantial strain on Bayer’s 
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business. On the other hand, if we had waited, even fewer attractive acquisition targets would 
have been available for Bayer. 
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(Source: Bayer & Monsanto Annual Report, 2013-2016) 
EXHIBIT 4.1    Balance Sheet Monsanto & Bayer 
€/$ million
In Millions of EUR except Per Share 2013 2014 2015 2013 2014 2015 2016
12/31/2013 12/31/2014 12/31/2015 08/31/2013 08/31/2014 08/31/2015 08/31/2016
Assets
Cash and cash equivalents 1,662            1,853             1,859             3,922            2,407            3,748            1,736           
Trade and other receivables 7,569            9,097             9,933             1,715            2,014            1,636            1,926           
Inventories 7,129            8,478             8,550             2,947            3,597            3,496            3,241           
Other short-term assets 2,094            2,407             3,016             1,469            1,558            1,668            1,221           
Derivative & hedging assets 574               392                463                24                 99                 77                 33                
Total Current Assets 19,028          22,227           23,821           10,077          9,675            10,625          8,157           
Property and equipment 28,455          31,319           33,540           9,491            10,357          10,428          11,116         
Accumulated depreciation (18,440)         (19,891)          (21,165)          (4,837)           (5,275)           (5,455)           (5,885)          
Long-term receivables -                -                 -                 237               92                 42                 -               
Goodwill 9,862            15,347           16,096           3,520            4,319            4,061            4,020           
Other intangible assets 8,914            15,653           15,178           1,226            1,554            1,332            1,125           
Deferred tax assets 1,596            3,802             4,679             454               450               277               613              
Derivative & hedging assets 191               92                  63                  -                31                 8                   4                  
Investments in affiliates 203               223                246                -                -                -                -               
Misc long-term assets 1,508            1,462             1,459             496               715               602               586              
Total Assets 51,317          70,234           73,917           20,664          21,918          21,920          19,736         
Liabilities and equity
Accounts payable 4,574            5,808             6,868             995               1,111            836               1,006           
Short-term debt 3,324            3,080             2,823             51                 233               615               1,587           
Deferred revenue -                -                 -                 517               438               370               568              
Derivatives & hedging 117               296                598                93                 23                 61                 69                
Income Taxes Accrued/Payable -                -                 -                 91                 99                 234               41                
Accrued marketing programs -                -                 -                 1,078            1,394            1,492            1,736           
Dividends Accrued/Payable -                -                 -                 228               239               254               237              
Grower Production Accruals -                -                 -                 60                 54                 39                 45                
Accrued Compensation & benefits -                -                 -                 492               500               304               239              
Customer Payable -                -                 -                 12                 82                 72                 104              
Restructuring Reserves -                -                 -                 -                -                170               246              
Misc short-term liabilities 6,008            6,319             6,691             719               939               730               851              
Total Current Liabilities 14,023          15,503           16,980           4,336            5,112            5,177            6,729           
Long-term debt 5,396            18,136           16,346           2,061            7,465            8,429            7,453           
Pension liabilities 7,368            12,236           10,873           357               345               336               371              
Deferred revenue -                -                 -                 138               47                 47                 35                
Deferred tax liabilities 1,193            689                826                469               509               340               68                
Derivatives & hedging 194               348                167                -                -                -                -               
Misc. LT Liabilities 2,339            3,104             3,280             575               526               586               535              
Common stock 2,117            2,117             2,117             6                   6                   6                   6                  
Paid-in capital 6,167            6,167             6,167             10,783          10,003          11,464          11,626         
Treasury stock -                -                 -                 (4,140)           (10,032)         (12,053)         (15,053)        
Retained earnings 14,817          12,974           16,581           7,188            9,012            10,374          10,763         
Other equity (2,383)           (1,152)            (600)               (1,278)           (1,114)           (2,801)           (2,808)          
Minority/Noncontrolling interest 86                 112                1,180             169               39                 15                 11                
Total liabilities & equity 51,317          70,234           73,917           20,664          21,918          21,920          19,736         
Bayer (EUR) Monsanto (USD)




(Source: Bayer & Monsanto Annual Report, 2013-2016) 
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EXHIBIT 4.2    Income Statement Monsanto & Bayer 
€/$ million
In Millions of EUR except Per Share 2013 2014 2015 2013 2014³ 2015² 2016¹
12/31/2013 12/31/2014 12/31/2015 08/31/2013 08/31/2014 08/31/2015 08/31/2016
Revenue 40,817       41,754       46,936           14,861         15,855         15,001           13,502           
Cost of goods sold (19,516)      (19,909)      (21,158)          (7,208)          (7,281)          (6,819)            (6,485)            
   Depreciation & amortization 2,896         2,920         3,333             615              691              716                727                
Selling, general & administrative (12,135)      (12,335)      (14,402)          (2,550)          (2,751)          (2,686)            (2,833)            
Research & development (3,406)        (3,537)        (4,281)            (1,533)          (1,725)          (1,580)            (1,512)            
EBIT 5,760         5,973         7,095             3,570           4,098           3,916             2,672             
Interest expense (602)           (618)           (752)               (172)             (248)             (433)               (436)               
Interest Income 257            283            297                92                102              105                74                  
Other non-operating income (loss) (334)           (646)           (550)               (61)               (101)             (34)                 (22)                 
Abnormal gains (losses) (874)           (578)           (845)               -               (24)               (393)               (297)               
Earnings before taxes 4,207         4,414         5,245             3,429           3,827           3,161             1,991             
Income tax (1,644)        (1,305)        (2,258)            (789)             (1,123)          (1,152)            (667)               
Deferred income tax 623            234            1,031             (126)             45                288                (28)                 
Earnings from continuing operations 3,186         3,343         4,018             2,514           2,749           2,297             1,296             
Discontinued operations -             100            80                  11                13                28                  17                  
Minority interest 3                (17)             12                  (43)               (22)               (11)                 23                  
Net Income 3,189         3,426         4,110             2,482           2,740           2,314             1,336             
Share price 100.00 €        102.42$          
Shares outstanding 826,947,808  438,178,000  
Bayer (EUR) Monsanto (USD)
(1) In 2016, the company recorded $67 million of cost of goods sold expenses related to the 2015 Restructuring Plan, $297 million of restructuring charges and $270 
million of selling, general and administrative expenses related to environmental and litigation settlements and a SEC settlement.
(2) In 2015, Monsanto recorded $100.5 million of cost of goods sold expenses related to restructuring, $167.3 million of selling, general and administrative expenses 
related to environmental and litigation settlements and a potential SEC settlement, and $392.7 million of restructuring expense. The company also recorded $274 million 
of net sales as a result of the sale of a perpetual license to intellectual property.
(3) In 2014, Monsanto recorded $31.8 million of selling, general and administrative expenses related to legacy environmental settlements.
EXHIBIT 4.3   Tax Reconciliation Monsanto Company
$ million
2016 2015 2014 2013
U.S. Federal Statutory Rate 697                  1,106           1,339                  1,200           
U.S. Domestic Manufacturing Deduction (64)                  (87)               (75)                     (68)               
U.S. R&D Tax Credit (34)                  (30)               (12)                     (43)               
U.S. State Income Taxes 28                    39                45                       43                
Lower Taxes on Foreign Operations (243)                (209)             (230)                   (78)               
Valuations Allowances 308                  13                12                       -               
Adjustments for Unrecognized Tax Benefits (6)                    (4)                 (8)                       (110)             
Other 9                      36                7                         (29)               
Income Tax Provision 695                  864              1,078                  915              




(Source: Monsanto Annual Report, 2016-2013) 
 
(Source: Monsanto Annual Report, 2016-2013) 
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EXHIBIT 4.4   Deferred Income Tax Balance Monsanto Company
$ million
2016 2015 2014 2013
Net Operating Loss and Other Carryforwards 438              323              443              455              
Employee Fringe Benefits 331              305              259              335              
Restructuring and Impairment Reserves 155              242              135              137              
Inventories 91                173              106              130              
Royalties 189              154              129              99                
Allowance for Doubtful Accounts 77                72                70                95                
Environmental and Litigation Reserves 70                69                69                71                
Intangibles -               -               74                46                
Other 407              307              350              239              
Valuation Allowance (346)             (68)               (63)               (47)               
Total Deferred Tax Assets 1,412           1,577           1,572           1,560           
Property, Plant and Equipment 533              539              585$            571$            
Intangibles 334              361              400              403              
Other -               -               81                60                
Total Deferred Tax Liabilities 867              900              1,066           1,034           
Net Deferred Tax Assets 545              677              506              526              
EXHIBIT 4.5    Intangible Assets Monsanto Company
$ million 2016 2015 2014
Acquired Germplams 1,070               (778)                  292    1,074           (750)             324    1,116              (751)             365    
Acquired Intellectual Property 1,042               (593)                  449    1,168           (598)             570    1,160              (507)             653    
Trademarks 334                  (152)                  182    353              (152)             201    366                 (142)             224    
Customer Relationships 301                  (223)                  78      318              (212)             106    338                 (204)             134    
Other 65                    (33)                    32      176              (146)             30      181                 (106)             75      
Total Other Intangible Assets, Finite Lives 2,812               (1,779)               1,033 3,089           (1,858)          1,231 3,161              (1,710)          1,451 
In Process R&D, Indefinite Lives 92                    -                    92      101              -               101    103                 -               103    













EXHIBIT 4.6    Others Monsanto Company
$ million
2017 2016 2015 2014 2013
Rental expenses 249                   256                 273               272              259                   
Amortization 116                 143               136              111                   
Divident payments 964                 938               904              802                   
Customer Financing Program 644                 1,050            574              437                   
Long-term debt Yield
MON 3.95 04/15/45 Corp 4.750%
Exchange rate
EUR/USD 1.05                




(Source: Monsanto Annual Report, 2016-2013) 
 
 
(Source: Monsanto Annual Report, 2016-2013) 
       
(Source: Bloomberg Terminal, as of 11/21/2016) 
 
 
(in USD millions) 2013 2014 2015 2016
Revenue 14,861 15,855 15,001 13,502
  United States 8,044 8,625 8,612 8,008
  Latin America 3,354 3,565 3,268 2,856
    Brazil 1,547 1,778 1,725 1,437
    Argentina 1,121 1,092 871 856
    Mexico 466 503 537 436
    Other 220 192 135 127
  Europe-South Africa 2,042 2,192 1,834 1,536
  Canada 615 636 601 619
  Asia-Pacific 806 837 686 483
EXHIBIT 4.6   Monsanto Sales by Geography
EXHIBIT 4.7   Monsanto Segments
(in USD millions) 2013 2014 2015 2016
   Seeds and Genomics 10,340 10,740 10,243 9,988
     Corn Seed and Traits 6,596 6,401 5,953 5,825
     Soybean Seed and Traits 1,653 2,102 2,276 2,162
     Vegetable and Fruit Seed 821 867 816 801
     All Other Crops Seeds and Traits 575 705 675 760
     Cotton Seed and Traits 695 665 523 440
   Agricultural Productivity 4,521 5,115 4,758 3,514
Total Sales 14,861 15,855 15,001 13,502








EXHIBIT 5.2   Expected Inflation
North America 59% 2,1%





Market ShareCountry Exp. Inflation
EXHIBIT 5.3   Full year forecast (vs. USD)
Full year forecast (vs. USD)
2017 2018 2019 2020
BRL 0,30 0,29 0,28 0,28
EUR 1,09 1,15 1,17 1,19
ARS 0,06 0,05 0,05 0,05
(source: Bloomberg, as of 11/21/2016)








(Source: Bayer Annual Report, 2015) 
 
 
(Source: Bloomberg Terminal, 01/01/2017)  
(source: Bloomberg, Doane, USDA) 2020 2019 2018 2017 2016 2015 2014 2013
U.S. Corn (Mn bushels)
    Acreage Planted (Mn acres) 90             90             90             91             94             88             91             95             
    Yield (bushels/acre) 177            175            173            171            172            168            171            158            
    Total Supply 16,565       16,445       16,400       16,466       16,665       15,397       15,479       14,686       
    Total Use 14,495       14,585       14,405       14,265       14,405       13,663       13,748       13,455       
    Avg. Crop Price ($/bushel) 3.50             3.50             3.45             3.30             3.25             3.61             4                  4                  
U.S. Soybean (Mn bushels)
    Acreage Planted (Mn acres) 85             85             84             84             83             83             77             
    Yield (bushels/acre) 48             47             47             49             48             48             44             
    Total Supply 4,360         4,315         4,275         4,365         4,145         4,052         3,570         
    Total Use 4,060         4,005         3,950         4,020         3,890         3,862         3,478         
    Avg. Crop Price ($/bushel) 10                10                9                  9                  9                  10                13                
U.S. Wheat (Mn bushels)
    Acreage Planted (Mn acres) 51             51             50             49             50             55             57             56             
    Yield (bushels/acre) 48             48             47             47             53             44             44             47             
    Total Supply 2,890         2,955         3,080         3,220         3,400         2,927         2,767         3,026         
    Total Use 2,250         2,250         2,270         2,245         2,226         1,952         2,015         2,436         
    Avg. U.S. Crop Price ($/bushel) 6                  6                  6                  6                  5                  6                  7                  
    
U.S. Cotton (1000 480 lb. bales)
    Acreage Planted (Mn acres) 10,750,000 10,750,000 10,500,000 10,500,000 10,145,000 8,581,000   11,037,400 10,407,000 
    Yield (lbs/acre) 830            825            820            815            797            766            838            821            
    Total Supply 19,605       19,608       19,385       19,591       19,844       16,568       18,680       16,719       
    Total Use 16,150       15,900       15,650       15,600       15,500       12,600       14,830       14,080       
    Avg. Crop Price (cents/lb.) 68                67                66                65                64                58                61                78                
EXHIBIT 5.4   U.S Agriculture Supply/Demand Forecast
EXHIBIT 6   Bayer Management Report & Annexes
19. Takeover-Relevant Information
Explanatory report pursuant to Sections 289, Paragraph 4 and 315, Paragraph 4 of the German Commercial Code (HGB)
The capital stock of Bayer AG amounted as of December 31, 2015 to €2,117 million, divided into 826,947,808 no-par registered shares. 
The capital stock and the number of shares were thus unchanged from the end of the previous year. Each share confers one voting right. 
[...]
Provisions of the Articles of Incorporation concerning Authorized Capital I and Authorized Capital II are entered in the commercial 
register of Bayer AG. With the approval of the Supervisory Board and until April 28, 2019, the Board of Management may use the 
Authorized Capital I to increase the capital stock by up to a total of €530 million. New shares may be issued against cash contributions 
and / or contributions in kind, but capital increases against contributions in kind may not exceed a total of €423 million. If the Authorized 
Capital I is used to issue shares in return for cash contributions, stockholders must normally be granted subscription rights. [...]
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The main objective of the case is to do an M&A valuation of the Bayer Monsanto deal. This 
includes a company valuation of Monsanto using the DCF method in order to decide whether 
the premium Bayer paid to the current share price can be justified. Further tasks include 
answering questions with strategic relevance as well as other M&A-related questions including 
the financing of the transaction. This case is applicable for any Corporate Finance, M&A or 
Valuation class. 
Relevant Literature 
Koller, T., Goedhart, M., & Wessels, D. (2011). Valuation - Measuring and Managing the Value 
of Companies. Hoboken: John Wiley & Sons, Inc.  
Monsanto (2015). Annual Report. St. Louis: Monsanto Company. 
Bayer (2015). Annual Report. Leverkusen: Bayer AG. 
DeMarzo, P., & Berk, J. (2014). Corporate Finance. Boston: Pearson. 
Marks, Kenneth et al. (2005). The Handbook of Financing Growth – Strategies and Capital 
Structure. Hoboken: John Wiley & Sons. 
Diverse FT, Bloomberg News, WSL articles 
Suggested Questions 
1. Valuing Monsanto Company using the DCF method. Include mentioned synergies.   
2. Financing: 
a. Risks of financing the deal and evaluation of Bayer proposal 
b. How to successfully issue the planned amount of equity? What is the max 
discount for the new shares to avoid a shareholder vote? 
c. How will the share price be affected? 
3. Strategy: 
a. Was the decision to acquire Monsanto right? Would there be alternatives?  
b. How will the competition most likely react?  
c. Are there other factors that have not yet been considered? 
 




Q1. Valuing Monsanto Company using the DCF method 
Reorganizing Financial Statements & NOPLAT Calculation 
The first step for the company valuation using the discounted cash flow (DCF) method is to 
reorganize the financial statements and separate operating from non-operating assets in order 
to calculate the free cash flows (FCF). As per definition (Koller, Goedhart, & Wessels, 2011), 
FCFs are independent from non-operating assets as well as from financing.  
𝐹𝐶𝐹 = 𝑁𝑂𝑃𝐿𝐴𝑇 + 𝑁𝑜𝑛𝑐𝑎𝑠ℎ 𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝐸𝑥𝑝𝑒𝑛𝑠𝑒 − 𝐼𝑛𝑣𝑒𝑠𝑡𝑚𝑒𝑛𝑡𝑠 𝑖𝑛 𝐼𝑛𝑣𝑒𝑠𝑡𝑒𝑑 𝐶𝑎𝑝𝑖𝑡𝑎𝑙 
To calculate the net operating profits less adjusted taxes (NOPLAT), the income statement needs 
to be adjusted for operating costs and operating taxes. This requires a thorough analysis of the 
company’s financial statements as well as the footnotes included. In 2016, the company 
reported $67 million restructuring expenses as part of COGS. In 2015, Monsanto reported $101 
million of restructuring expenses as part of COGS as well as a $274 million sale of a perpetual 
license which has been recorded as part of revenue. Furthermore, Monsanto’s selling, general 
& administrative expenses (SG&A) need to be adjusted for litigation and environmental 
settlement outlays which are $32, $167 and $270 million respectively in 2014, 2015 and 2016 
as well as for $392.2 and $297 million restructuring expense in 2015 and 2016 (Exhibit 4.2).  
Subtracting the adjusted operating expenses from the net sales leads to the company’s EBIT. 
For the FCF calculation, it is recommended to use EBITA because the accounting for intangibles 
differs from physical assets. The amortization values from the cash flow statement are shown 
in Exhibit 4.6. Intangibles are expensed and not capitalized, and thus using EBITA avoids 
double-counting amortization expenses (Koller, Goedhart, & Wessels, 2011).  
NOPLAT is calculated by subtracting Monsanto’s operating taxes as well as the change in 
deferred taxes from its EBITA (refer to chapter “Tax adjustments” for operating tax calculation).  




Table 1: Net Operating Profit less Adjusted Taxes (NOPLAT) Calculation for Monsanto 
Tax adjustments 
Operating Taxes 
In order to calculate the operating taxes, we have to find the tax reconciliation table in the 
financial report, convert reported values into percentages and eliminate non-operating and one-
time taxes (Exhibit 4.3). The adjustment for operating taxes requires judgement in many cases. 
As a proxy for the marginal tax rate we can use the statutory rate plus the state tax (Koller, 
Goedhart, & Wessels, 2011) which sums up to 36.4% for Monsanto in 2016 (taken from the tax 
reconciliation table of the annual report, Exhibit 4.3). As amortization is usually nondeductible 
from taxes, we calculate the operating taxes as a function of Monsanto’s adjusted EBITA which 
results into marginal taxes of $1.197 million in 2016. For the operating taxes, we have to take 
into account tax benefits that the company is exposed to such as tax credit for R&D expenditures 
or lower foreign rates as a result of business operations in other countries with lower tax rates 
than the U.S. For the Monsanto analysis, all the reported taxes can be considered operating 
except for those reported as “Other, net”. There is no further description of this type of taxes in 
the financial report, however the values seesaw significantly which is why it is excluded from 
the analysis. Adjusting the marginal tax rate for the tax benefits leads to an operating tax rate 
of 35% in 2016 as can be seen in Table 2.  
(Dollars in millions) 2013 2014 2015 2016
Net Sales 14,861          15,855          15,001          13,502         
  Cost of goods sold 7,208            7,281            6,819            6,485           
       Thereof perpetual license sale (274)              
       Thereof expenses related to restructuring -                -                (101)              (67)              
Gross Profit 7,653            8,574            7,808            6,950           
Operating Expenses:
  Selling, general & administrative expenses 2,550            2,774            2,686            2,833           
     Thereof expenses for litigation & environmental settlements -                (32)                (167)              (270)            
     Thereof expenses related to restructuring (392)              (297)            
  Research & development expenses 1,533            1,725            1,580            1,512           
Total Operating Expenses 4,083            4,467            3,707            3,778           
EBIT 3,570            4,107            4,101            3,172           
Amortization 111               136               143               116              
EBITA 3,681            4,243            4,244            3,288           
Operating Taxes 1,035            1,221            1,220            1,158           
+/- Change in Deferred Taxes 27                 38                 (113)              76                
NOPLAT 2,673$          3,059$          2,911$          2,206$         




Table 2: Operating Taxes for Monsanto 
Deferred Taxes 
For a more accurate valuation, it makes sense to use the operating cash taxes that were actually 
paid instead of simply using the reported accrual-based taxes. This deviation exists mainly due 
to accounting differences in taxation and reporting. For example, the government allows an 
accelerated depreciation to reduce tax burden in the beginning of an asset life while the figures 
in the financial statement are usually reported using straight-line depreciation, thus overstating 
actual taxes (Koller, Goedhart, & Wessels, 2011). 
The easiest way to calculate the cash taxes is to subtract the delta in net operating deferred tax 
liabilities (DTLs). The deferred income tax balances can be found in the same footnote as the 
tax reconciliation table (Exhibit 4.4). Monsanto has one operating-related DTA (deferred tax 
assets) and one DTL. The first one is reported as property, plant and equipment (PP&E) and 
refers to accelerated depreciation (a DTL). The second one refers to inventories (a DTA) as a 
result of differences in inventory valuation between tax and financial accounting. Subtracting 
the DTA from the DTL yields net operating deferred-tax liabilities of $442 million in 2016. The 
remaining items in the deferred income tax table are related to non-operating DTAs and DTLs 
as highlighted in Table 3.  
(Dollars in millions) 2013 2014 2015 2016
Operating Taxes and Operating Cash Taxes
Marginal Tax Rate 36.2% 36.2% 36.2% 36.4%
   x Adjusted EBITA 3,681        4,243        4,244        3,288        
= Marginal taxes on EBITA 1,334        1,534        1,537        1,197        
Other Operating Taxes: (299)$       (313)$       (317)$       (39)$         
   Lower Foreign rates (78)$         (230)$       (209)$       (243)$       
   U.S. Domestic Manufacturing Deduction (68)$         (75)$         (87)$         (64)$         
   U.S. R&D Tax Credit (43)$         (12)$         (30)$         (34)$         
   Valuation Allowances -$         12$           13$           308$         
   Adjustment for Unrecognized Tax Benefits (110)$       (8)$           (4)$           (6)$           
Operating Taxes 1,035$      1,221$      1,220$      1,158$      
Operating tax rate 28% 29% 29% 35%




Table 3: Deferred income tax reorganization 
In 2015, Monsanto reported an increase of $76 million in operating deferred taxes and thus 
operating cash taxes of $1.234 million.   
 
Table 4: Operating Cash Taxes 
Free Cash Flow Calculation 
Moving forward from NOPLAT, we need to add back the non-cash operating expenses and 
subtract the investments in invested capital. Adding back depreciation to NOPLAT, yields 
Monsanto’s gross cash flow of $2,770 in 2016 (refer to Table 5). This is the cash flow generated 
solely by the company’s operations. In other words, it is the cash that is available for investment 
without the need to raise any additional capital (Koller, Goedhart, & Wessels, 2011). 
Investments in invested capital include the change in operating working capital, net capital 
expenditures, the change in capitalized operating leases, investments in goodwill and acquired 
intangibles as well as the change in net long-term operating assets. As each of these items 
requires special treatment, the following chapters are dedicated to analyze these in detail. In 
2016, Monsanto reported a FCF of $2.441 million as can be seen in Table 5. 
Deferred income tax balances are related to 2013 2014 2015 2016
Tax loss carry-forwards
  Net operating losses 455$        443$        323$        438$        
  Valuation allowance (47)          (63)          (68)          (346)        
Tax loss carry-forwards 408          380          255          92            
600          
Operating deferred taxes
  Accelerated depreciation 571          585          539          533          
  Accelerated inventory deduction 130          106          173          91            
Net operating deferred-tax liabilities 441$        479$        366$        442$        
Nonoperating deferred taxes
  Goodwill and other intangibles (357)        (326)        (361)        (334)        
  Other deferred-tax liabilities 60            81            -          -          
  Other deferred-tax assets 976$        1,012$     1,149$     1,229$     
Nonoperating deferred-tax  (liabilities) 559$        605$        788$        895$        
Deferred-tax assets (liabilities) 526          506          677          545          
2013 2014 2015 2016
Operating taxes 1,035$      1,221$      1,220$      1,158$      
Increase in operating deferred taxes 27$           38$           (113)$       76$           
Operating Cash Taxes 1,062$      1,259$      1,107$      1,234$      




Table 5: Free Cash Flow Calculation 
Operating Working Capital Calculation 
Operating working capital refers to the investment in inventory, operating cash and other 
working capital components. To be consistent in the calculation, we need to exclude non-
operating items such as excess cash2, short-term debt, derivatives & hedging or dividends.  
With $1.466 million in 2016, Monsanto holds a significant amount of excess cash which needs 
to be subtracted from the company’s cash and cash equivalents reported on the balance sheet. 
Further operating items on the asset side of the balance sheet include accounts receivables, misc. 
receivables, inventory as well as other current assets.  
On the liabilities side of the balance sheet, we have to include the accrued income taxes, the 
marketing and grower production programs, deferred revenue, compensation, as well as 
accounts and customer payables. 
Subtracting the total current operating liabilities from the assets results into a working capital 
balance of $1.958 million in 2016. 
                                                 
2 Based on the S&P 500 average, excess cash is defined as any cash balance held by the company that exceeds 
2% of sales 
(Dollars in millions) 2014 2015 2016
NOPLAT 3,059            2,911         2,206           
Depreciation 555               573            563              
Gross Cash Flow 3,614            3,484         2,770           
Change in operating working capital 650               (193)           (403)            
Net capital expenditures 983               464            821              
Decrease (increase) in capitalized operating leases (7)                  (249)           336              
Investments in goodwill and acquired intangibles 928               (332)           (327)            
Decrease (increase) in net long-term operating assets 290               (139)           (99)              
Gross investment 2,844            (449)           329              
Free cash flow 770               3,933         2,441           




Table 6: Operating working capital calculation 
Net Capital Expenditures 
Net capital expenditures (capex) can be calculated by subtracting last year’s net PP&E asset 
value from this year’s and adding back depreciation of the current year. For Monsanto this 
results into a net capex of $821 million in 2016 (Table 5).  
Capitalized Operating Leases 
Companies usually do not disclose the value of their operating leases but rather record the 
asset’s rental expenses as well as future commitments of rental charges. For the valuation, the 
lease value should be included as an operating asset or otherwise companies that lease instead 
of buying assets appear to be “capital light”. As the values are not disclosed, we can estimate 
the asset value by using the formula (Koller, Goedhart, & Wessels, 2011): 






The rental expenses are reported in the footnotes (Exhibit 4.6), while the cost of debt calculation 
will be explained in detail in the WACC calculation chapter. The asset life can be approximated 
by dividing total PP&E by the depreciation expense for the respective year. In 2017, Monsanto 
(Dollars in millions) 2013 2014 2015 2016
Current Assets 4                   5                6                  7                   
     Cash and cash equivalents 3,922            2,407         3,748           1,736            
       - Excess Cash (3,625)           (2,090)        (3,448)         (1,466)          
     Trade receivables, net 1,715            2,014         1,636           1,926            
     Derivatives and Hedging 24                 99              77                33                 
     Inventory, net 2,947            3,597         3,496           3,241            
     Other current assets 166               205            199              227               
Total Current Assets 5,149            6,232         5,708           5,697            
Current Liabilities
     Income Taxes Accrued/Payable 91                 99              234              41                 
     Accrued marketing programs 1,078            1,394         1,492           1,736            
     Deferred/Unearned Revenue (Short-Term) 517               438            370              568               
     Grower Production Accruals 60                 54              39                45                 
     Accrued Compensation & benefits 492               500            304              239               
     Customer Payable 12                 82              72                104               
     Accounts Payable 995               1,111         836              1,006            
Total Current Liabilities 3,245            3,678         3,347           3,739            
Working Capital 1,904            2,554         2,361           1,958            
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has a rental expense of $249 million. In 2016, the company records an average asset life of 19.7 
years and an after-tax cost of debt of 3%, resulting into an asset value of $3.031. 
 
Table 7: Operating Leases 
Investments in Goodwill and Acquired Intangibles 
We can estimate the investment in goodwill and acquired intangibles by computing the change 
in net goodwill and acquired intangibles. In addition, cumulative amortization has to be added 
back for intangible assets that are amortized. For Monsanto, this leads to a total of $6.924 
million in 2016 as shown in Table 8.  
 
Table 8: Adjustments to Goodwill and Acquired Intangibles 
Change in net long-term operating assets 
Investments in other net operating assets have to be taken into consideration as well. For 
Monsanto, other long-term assets have to be netted against other liabilities. The delta yields    
-$99 million in 2016 (Table 5). 
Forecasting 
Revenues 
Now that we have calculated Monsanto’s FCFs, we need to forecast these values to determine 
the value of the company. Most importantly, we have to forecast Monsanto’s revenues as most 
remaining income statement and balance sheet items will be a function of these. At this point, 
it is important to mention that forecasting is never a precise science. As for case study purposes, 
it is important that forecasts are undermined with a logical and reasonable explanation. The 
Operating leases
(Dollars in millions) 2014 2015 2016
Rental Expense 272 273 256
Asset life 18.7 18.2 19.7
Cost of Debt 3% 3% 3%
Asset value 3,232         2,983           3,049            
(Dollars in millions) 2014 2015 2016
Goodwill 4,319         4,061           4,020            
Acquired Intangibles 1,554         1,332           1,125            
Cumulative amortization and impairments 1,710         1,858           1,779            
Adjustments to Goodwill and Acquired Intangibles 7,583         7,251           6,924            
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following abstract in this teaching note will give an example. 
As mentioned before, Monsanto consists of two main business: The Seeds and Genomics 
segments makes up around 74% of Monsanto’s total business while Crop Protection makes up 
the remaining 26%. Each business has separate value drivers which will be highlighted and 
forecasted in this chapter. Overall, sales are driven by the three influencing factors volume, 
price and currency impacts.  
The currency impact can be estimated by weighting the forecasted exchange rates with 
Monsanto’s market share in the respective countries. Exhibit 5.3 shows the 3 major currencies 
that impact Monsanto’s revenues. The revenue generated in the U.S. (59%), Brazil (11%), 
Argentina (6%) and in the Euro area (11%) already sum up to 88% of Monsanto’s total turnover. 
As there is no currency impact from the U.S., only the latter three have to be taken into account. 
Furthermore, we can assume that the currency risk that Monsanto has in these countries comes 
from accounts receivables (farmers paying Monsanto for their products). Thus, a depreciation 
of the real, peso or euro has negative impacts for the company. Table 9 shows that by converting 
the values given in Exhibit 5.3 into percentages and by multiplying these with Monsanto’s 
market share in 2016 (Exhibit 4.4), the projected FX impact can be calculated for the following 
years. 
 
Table 9: Projected FX Impact 
Price/Volume Crop Protection: One of the main drivers of crop protection turnover is the 
farmer’s income. If crop prices are high, farmers have more purchasing power in what regards 
branded crop protection chemicals. As crop prices have been depressed in the past 3 years due 
to strong harvests in the Americas, farmers increasingly moved to generic crop protection 
products which led ultimately to depressed sales for Monsanto. The forecast assumption that is 
2016 2017 2018 2019 2020 Market Share
BRL 2% -3% -3% 0% 11.0%
EUR -2% 6% 2% 2% 12.0%
ARS -14% -7% -9% 0% 6.0%
Overall FX Impact -0.8% -0.1% -0.6% 0.2%
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made here is that crop prices strongly correlate with herbicide sales. According to the U.S. 
Department of Agriculture, crop prices are estimated to be even lower in the next three years, 
while slowly starting to pick up again in 2019 (Exhibit 5.4).  
As Monsanto lost its remaining glyphosate patents in 2000, there has been an immense increase 
in glyphosate production, leading to oversupply in the market and thus even further margin 
deterioration. As a result, the forecast assumption for the valuation is that revenue from 
herbicides will decrease -3% and -1% in 2017 and 2018 respectively, while remaining at 0% in 
2019 and slowly picking up again in 2020 with 1% increase (Table 10).  
 
Table 10: Crop Protection Revenue Forecast 
In contrast to the Crop Protection, Monsanto’s Seed segment has slightly different value drivers. 
One main influencing factor is the expansion in acreage that is available for planting as a logical 
consequence of the more space available, the more seeds for plantation are required. At this 
point, one also has to take the market size of the main crops into consideration as well as weather 
forecasts and company own expansion plans:  
Monsanto’s Seed business can roughly be divided into corn, soy, cotton and other seeds. 
Monsanto’s corn business makes up more than 50% of its total seed business and is by far the 
most advanced in terms of genetically modified variations as for example drought tolerance. 
Weather is always hard to forecast, but following the 2016 El Niño, the weather phenomenon 
La Niña is expected to show her impact by the end of 2016 and the beginning of 2017. La Niña 
lowers the average equatorial Pacific Ocean water temperature and is associated with an 
increase in droughts in the Americas as well as an increase in rain in Australia and Asia. As 
Incl. fx effect Excl. fx effect
Year Currency Effect Herbicide Sales Herbicide Sales Herbicide Sales ∆
2014 -2.2% 5,115              5,230               13%
2015 -4.9% 4,758              4,992               -5%
2016 -5.1% 3,514              3,692               -26%
2017 -0.8% 3,551              3,581               -3%
2018 -0.1% 3,542              3,545               -1%
2019 -0.6% 3,523              3,545               0%
2020 0.2% 3,588              3,580               1%
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Monsanto’s biggest market is North and South America (~80% of sales), an increase in drought 
resistant corn seeds can be expected. However, there will be a slight headwind as a result of 
decreasing acreage in 2017 and 2018. After that we can only expect slow growth due to 
continuously depressed corn prices as well as a slow expected growth in acreage. Thus the corn 
forecast for the next five years is 5%, 1%, 3% and 2% until 2020 respectively as shown in Table 
11.  
 
Table 11: Seed Sales Corn Forecast 
For soy seeds, Monsanto expects a 20% increase in sales in 2017 due to a newly introduced soy 
seed technology that already showed a favorable adoption rate in Latin America. However, 
from personal judgement as well as depressed farmers’ spending, this number seems 
overestimated. Therefore, the assumption is that the 20% increase in sales will be reached only 
until 2018 with an approximate 10% sales increase each year. This is followed by 2% growth 
as well as 5% growth in 2019 and 2020 respectively due to an increase in available acreage.  
 
Table 12: Forecast Seed Sales Soy 
Monsanto’s cotton sales show a high correlation of 71% between planted acreage and seed sales. 
Thus the best forecast for the cotton sales will be in accordance to the acreage forecast of 3%, 
Incl. fx effect Excl fx effect
Year Currency Effect Corn Sales Corn Sales Corn Sales ∆
2014 -2% 6,401                   6,542               -3%
2015 -6% 5,953                   6,318               -3%
2016 -3% 5,825                   6,000               -5%
2017 -1% 6,248                   6,300               5%
2018 0% 6,357                   6,363               1%
2019 -1% 6,512                   6,553               3%
2020 0% 6,698                   6,685               2%
Incl. fx effect Excl fx effect
Year Currency Effect Soy Sales Soy Sales Soy Sales ∆
2014 -2% 2,102             2,148                  27%
2015 -6% 2,276             2,416                  12%
2016 -3% 2,162             2,227                  -8%
2017 -1% 2,429             2,449                  10%
2018 0% 2,692             2,694                  10%
2019 -1% 2,731             2,748                  2%
2020 0% 2,892             2,886                  5%
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0%, 2% and 0% respectively until 2020.  
 
Table 13: Forecast Seed Sales Cotton 
All the sales forecast figures are adjusted by the currency forecast of the most relevant 
currencies for Monsanto, namely the Brazilian real, euro and Argentine peso. 
The remaining revenues from Monsanto’s seed business are forecasted based on sales in 2016 
which summed up to 2%. Thus, the forecast is assumed to be constant 2% for the next years. 
The total sales are a sum of the forecasted values from crop protection, corn, soy, cotton and 
others and can be seen in the last column ‘Total Sales’ in Table 14. 
 
Table 14: Forecast Other Seed Sales & Total Sales 
Forecasting the Income Statement 
To forecast the income statement, we have to decide which economic relationship drives the 
line item. Most items are directly tied to the revenue, including COGS, SG&A and R&D. Some 
other items as for example depreciation or interest expenses are tied to a specific asset or 
liability on the balance sheet. 
In a next step, we need to estimate the forecast ratios for each line item, based on historical 
ratios. For example, Monsanto’s COGS to sales ratio was 44% in 2016. This level has been 
Incl. fx effect Excl fx effect
Year Currency Effect Cotton Sales Cotton Sales Cotton Sales ∆
2014 -2% 665 680                  -4%
2015 -6% 523 555                  -18%
2016 -3% 440                  453                  -18%
2017 -1% 463                  467                  3%
2018 0% 466                  467                  0%
2019 -1% 473                  476                  2%
2020 0% 477                  476                  0%
Incl. fx effect Excl fx effect
Year Currency Effect Other Sales Other Sales Other Sales ∆ Total Sales
2013 -2% 1,396               1,425               -3% 14,861          
2014 -2% 1,572               1,607               13% 15,855          
2015 -6% 1,491               1,582               -2% 15,001          
2016 -3% 1,561               1,608               2% 13,502          
2017 -1% 1,626               1,640               2% 14,249          
2018 0% 1,671               1,673               2% 14,660          
2019 -1% 1,695               1,706               2% 14,865          
2020 0% 1,744               1,740               2% 15,329          
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more or less constant in the previous years. Next, we set the forecast figure for 2017 also to 
44% and multiply this value by the forecasted sales figure. This leads to a COGS forecast of 
$6.249 million in 2017. 
The typical forecast driver for depreciation is the prior-year net PP&E, interest expenses are 
driven by prior-year total debt, while interest income is driven by prior-year excess cash or in 
Monsanto’s case by the customer financing program, as indicated by the footnotes. The fully 
forecasted income statement can be seen in Table 15. 
 
Table 15: Income Statement Forecast 
Forecasting the Balance Sheet 
To forecast the balance sheet, start by forecasting invested capital and non-operating assets. 
Excess cash and sources of financing are only forecasted in the end in order to make both sides 
of the balance sheet even. Again, we can forecast most line items as a function of revenues, 
starting with the operating working capital such as accounts receivables and accrued expenses. 
Two exceptions are inventories and accounts payable that can be forecasted as a function of 
COGS. 
Forecast net PP&E as a function of revenues and depreciation as a percentage of gross or net 
Income Statement Forecast
(Dollars in millions, except per share amounts) 2015 2016 2017 2018 2019 2020
Net Sales 15,001$           13,502$     14,249$      14,660$       14,865$        15,329$      
  Cost of goods sold 6,819               6,485         6,249$        6,429$         6,519$          6,723$        
     Thereof depreciation expense 573                  563            593$           625$            643$             652$           
Gross Profit 8,182$             7,017$       7,407$        7,605$         7,702$          7,953$        
Operating Expenses:
  Selling, general & administrative expenses 2,686               2,833         2,565$        2,639$         2,676$          2,759$        
  Research & development expenses 1,580               1,512         1,567$        1,613$         1,635$          1,686$        
  Restructuring charges 393                  297            -$            -$            -$              -$           
Total Operating Expenses 4,659$             4,642$       4,132$        4,251$         4,311$          4,445$        
Income from Operations 3,523               2,375         3,275$        3,354$         3,391$          3,508$        
   Interest expense 433                  436            436             436$            436$             436$           
   Interest income (105)                (74)             (51)$            (51)$            (51)$              (51)$           
   Other expenses, net 34                    22              51$             51$              51$               51$             
Income from Continuing Operations Before Income Taxes 3,161$             1,991$       2,839$        2,918$         2,955$          3,072$        
   Income tax provision 864                  695            1,095$        1,120$         1,133$          1,168$        
Income from Continuing Operations 2,297$             1,296$       1,744$        1,798$         1,822$          1,904$        
Discontinued operations:
   Income from operations of discontinued business 45                    27              27$             27$              27$               27$             
   Income tax provision 17                    10              10$             10$              10$               10$             
Income on Discontinued Operations 28                    17              17$             17$              17$               17$             
Net Income 2,325$             1,313$       1,761$        1,815$         1,839$          1,921$        
   Less: Net income attributable to noncontrolling interest 11                    (23)             -$            -$            -$              -$           
Net Income Attributable to Monsanto Company 2,314$             1,336$       1,761$        1,815$         1,839$          1,921$        




For goodwill and acquired intangibles we choose to keep these constant and set revenue growth 
from acquisitions to zero. This approach is preferred by practitioners as empirical literature 
suggests that typical acquisitions often fail to create value which makes forecasting goodwill 
and acquired intangibles unnecessary (Koller, Goedhart, & Wessels, 2011). Monsanto’s 
forecasted balance sheet can be seen below in Table 16. 




Table 16: Forecasted Balance Sheet 
 
Balance Sheet Forecast
(Dollars in millions, except per share amounts) 2015 2016 2017 2018 2019 2020
Assets
Current Assets
     Cash and cash equivalents 3,701$      1,676$      1,221$      1,621$       2,020$       2,321$    
        Operating cash 300           270           285           293            297            307         
        Excess cash 3,401        1,406        936$         1,328$       1,723$       2,014$    
     Short-term investments 47             60             60             60              60              60           
     Trade receivables, net 1,636        1,926        2,032        2,091         2,120         2,187      
     Miscellaneous receivables 803           755           797           820            831            857         
     Deferred tax assets 743           -            587           498            509            493         
     Inventory, net 3,496        3,241        3,123        3,213         3,258         3,360      
     Assets held for sale -            272           -            -             -             -          
     Other current assets 199           227           240           246            250            258         
Total Current Assets 10,625      8,157        8,060        8,550         9,049         9,535      
     Total property, plant and equipment 10,428      11,116      10,427      10,728       10,878       11,217    
     Less: Accumulated depreciation 5,455        5,885        4,907        5,048         5,119         5,279      
Property, Pland and Equipment, Net 4,973        5,231        5,520        5,680         5,759         5,939      
Goodwill 4,061        4,020        4,020        4,020         4,020         4,020      
Other Intangible Assets, Net 1,332        1,125        1,125        1,125         1,125         1,125      
Noncurrent Deferred Tax Assets 277           613           521           469            463            466         
Long-Term Receivables, Net 42             101           107           110            111            115         
Other Assets 610           489           516           531            538            555         
Total Assets 21,920$    19,736$    19,869$    20,484$     21,066$     21,754$  
Liabilities and Shareholder's Equity
Current Liabilities
     Income Taxes Accrued/Payable 234           41             41             41              41              41           
     Accrued marketing programs 1,492        1,736        1,417        1,458         1,478         1,525      
     ST Borrowings and Current Portion of LT Debt 615           1,587        1,587        1,587         1,587         1,587      
     Dividends Accrued/Payable 254           237           312           322            326            341         
     Deferred/Unearned Revenue (Short-Term) 370           568           427           440            446            460         
     Grower Production Accruals 39             45             48             49              50              52           
     Accrued Compensation & benefits 304           239           252           259            263            271         
     Customer Payable 72             104           100           103            105            108         
     Restructuring Reserves 170           246           -            -             -             -          
     Miscellaneous short-term accruals 791           920           971           999            1,013         1,045      
     Accounts Payable 836           1,006        969           997            1,011         1,043      
Total Current Liabilities 5,177        6,729        6,126        6,256         6,321         6,471      
Long-Term Debt 8,429        7,453        7,453        7,453         7,453         7,453      
Postretirement Liabilities 336           371           350           330            311            292         
Long-Term Deferred Revenue 47             35             37             38              39              40           
Noncurrent Deferred Tax Liabilities 340           68             68             68              68              68           
Long-Term Portion of Env. & Litigation Liab. 194           200           193           193 193            193         
Long-Term Restructuring Reserve 47             -            -            -             -             -          
Other Liabilities 345           335           652           695            761            824         
Shareowners' Equity:
       Outstanding 6 6               6               6 6 6
     Treasury stock (12,053)     (15,053)     (15,053)     (15,053)      (15,053)      (15,053)   
Additional contributed capital 11,464      11,626      11,543      11,460       11,376       11,293    
Retained earnings 10,374      10,763      11,291      11,836       12,388       12,964    
Accumulated other comprehensive loss (2,801)       (2,808)       (2,808)       (2,808)        (2,808)        (2,808)     
Total Monsanto Shareowners's Equity 6,990        4,534        4,979        5,440         5,909         6,402      
Noncontrolling Interest 15 11 11 11 11 11
Total Shareowners' Equity 7,005        4,545        4,990        5,451         5,920         6,413      
Total Liabilities and Shareowners' Equity 21,920$    19,736$    19,869$    20,484$     21,066$     21,754$  
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WACC & Continuing Value 
Now that we have forecasted the income statement, the balance sheet and thus the FCFs, we 
can move over to determine the discounting factor for Monsanto’s FCFs. For this purpose, we 
estimate the company’s weighted average cost of capital (WACC) based on Monsanto’s capital 
structure as well as cost of debt and equity.  
Cost of Equity 
The cost of equity can be estimated by using the capital asset pricing model (CAPM), which 
equates the risk-free rate, the company beta and the expected return of the market.  
Risk-free rate: The risk-free is ideally estimated by using a risk-free government bond with the 
same maturity as the DCF. For this purpose, we can use US Treasury yields with 1, 2, 3, 5, 10 
and 30 years’ maturity (Exhibit 5.1).  
Beta: Monsanto’s equity beta can be estimated by regressing the monthly stock returns of the 
past five years with the returns of MSCI World for the same time frame (data retrieved from 
Bloomberg Terminal). The regression is based on monthly returns in order to avoid systematic 
biases. This leads to a beta of 0.92 (Table 18). This beta however is quite imprecise as we can 
see that R2 only delivers a value of 25%. In order to improve the beta estimation, we use industry 
betas as we can assume that these companies face similar operating risks. The industry 
companies for comparison (Table 18) as well as respective share price data and foreign 
exchange rates can be retrieved from Bloomberg Terminal. To find the industry’s raw regression 
beta, we need to un-lever the individual betas in order to adjust for the company’s leverage and 
thus different financial risk3. According to the theory of Modigliani and Miller (1963), this can 
be done by multiplying the equity beta with the company’s debt to equity ratio using the 
following formula: 
                                                 
3 Please note that industry companies may be denominated in different currencies. In order to avoid distortions 
caused by currency fluctuations, it is recommended to subtract currency returns for the calculation of the raw 
regression betas (refer to tab “Industry Betas”) 
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The total debt can be estimated by subtracting excess cash from the company's total debt plus 
operating leases. The market value of equity is given by the current market capitalization using 
the share price multiplied by the share price outstanding (Table 17).  
 
Table 17: Debt-to-equity Calculation 
Now that the unlevered beta solely reflects the operating risk, we can average all betas across 
the industry, which results in an average unlevered beta of 0.59 for the seed and crop protection 
industry.  
To re-lever Monsanto’s beta we need to multiply the industry average unlevered beta by 1 plus 
Monsanto’s D/E ratio, which results in a beta of 0.74.  
 
Table 18: Beta calculation 
Monsanto Dupont Syngenta Dow Bayer BASF 
USD USD CHF USD EUR EUR
Short-term debt 1,587.00             1,165.00         553.07                  995.00                 3,099.94               4,473.66            
Long-term debt 7,453.00             7,642.00         3,218.33               16,215.00            17,949.54             12,214.17          
Operating leases 3,200.00             3,773.75         903.82                  7,516.67              5,019.87               9,206.92            
Less: Excess cash 1,405.96             4,797.40         882.47                  7,601.44              1,024.00               913.64               
Total net debt 10,834.04           7,783.35         3,792.76               17,125.23            25,045.34             24,981.10          
Share price ($) 102.42                70.32              394.13                  54.07                   97.01                    88.08                 
Shares outstanding 438.18                869.34            92.58                    1,121.38              826.95                  918.48               
Market value of equity 44,878.01           61,132.13       36,487.53             60,633.07            80,219.03             80,895.29          
Debt-to-equity ratio 0.24 0.13 0.10 0.28 0.31 0.31
Company Equity Beta D/E Unlevered Beta
Dupont 1.51 0.13 1.34
Syngenta 0.82 0.10 0.75
Vilmorin & CIE 0.59 0.72 0.34
Dow 1.19 0.28 0.93
Bayer 0.94 0.31 0.72
BASF 1.12 0.31 0.86
Nufarm 0.67 0.33 0.50
KWS 0.21 0.14 0.18
Yuan Longping High tech Agricu 0.04 0.04 0.04
Sakata Seed Corp 0.53 -0.08 0.58
Coromandel International Limited 0.75 0.35 0.56
Agrium Inc 0.49 0.45 0.34
Monsanto 0.92 0.24 0.74
Average Unlevered Beta 0.59
Relevered Monsanto Beta 0.74
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Expected Market Return: For the market risk premium (expected market return minus risk free 
rate), we can rely on historical estimates that range from 4.5 to 5.5% (Koller, Goedhart, & 
Wessels, 2011). For this valuation purpose, it was decided to apply an expected return of the 
market of 6.5%.  
After-Tax Cost of Debt 
We can estimate the cost of debt by looking at the yield of the company’s long-term bonds. 
Monsanto is rated A3 and BBB by Moody’s and S&P respectively and thus still accounts as 
investment grade. The company’s MON 3.95 04/15/45 bond yields approximately 4.75% 
(Exhibit 4.6), which is in accordance with the average yield spreads of corporate bonds over 
U.S. treasuries. According to Moody’s A-rating, a 30-year corporate bond should yield 4.2% 
while a BBB-rated bond yields 4.8% on average.  
Next, we need to incorporate the tax shield. This can be done by multiplying the cost of debt 
with 1 minus the statutory tax rate (Koller, Goedhart, & Wessels, 2011), yielding an after-tax 
cost of debt of 3% (Table 20). 
WACC 
In a next step we need to calculate the proportion of total capital. Total debt and the market 
value of equity have already been calculated in a previous step in order to determine the D/E 
ratio. Monsanto has a debt proportion of 19% ($10.834 million), while equity makes up the 
remaining 81% ($44.878 million). The company’s after-tax cost of debt sums up to 3%, while 
the cost of equity for the first year yields 4.7%, 4.8% for the second and so on (Table 19).  
 
Table 19: Monsanto Cost of Equity 
Going from there, the company’s WACC sums up to 4.4% for year one and two.  
Maturity 1 2 3 4 5 10 30
Risk-free rate 0.78% 1.1% 1.4% 1.3% 1.8% 2.3% 3.0%
Beta 0.74 0.74 0.74 0.74 0.74 0.74 0.74
Exp. Return of the market 6.50% 6.50% 6.50% 6.50% 6.50% 6.50% 6.50%
Expected return of security 5.04% 5.12% 5.19% 5.16% 5.30% 5.43% 5.60%




Table 20: WACC Calculation 
Continuing Value 








Where RONIC represents the expected rate of return on new invested capital but can, for 
simplicity reasons be set equal to the industry median ROIC of 5,5% (Koller, Goedhart, & 
Wessels, 2011). The growth rate can be estimated by summing the expected inflation rate (2.8%) 
and the expected long-term rate of consumption growth for seeds and crop protection chemicals 
(0.43%). This growth rate has been estimated based on the future average consumption growth 
in various crops weighted by their market share. The expected inflation per country has been 
weighted by Monsanto’s current market share.  
 

















Years 1 2 3 4 5 10 30
Debt 10,834.04     19% 4.75% 35.0% 3.09% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6%
Equity 44,878.01     81% 4.66% 4.66% 3.8% 3.8% 3.9% 3.9% 4.0% 4.1% 4.2%
WACC 55,712.05     100% 4.4% 4.4% 4.5% 4.5% 4.6% 4.7% 4.8%












North America 59.31% 2% Rice 142.5 17% 0.06%
South America 21.15% 5.70% Wheat 213.7 25% 0.14%
Europe 11.38% 1.50% Soy 97.9 12% 1.14%
Canada 5% 2% Cotton 7.2 1% 0.07%
Asia 3.58% 2.20% Coarse 385.9 46% 0.55%
Sumproduct 100% 2.8% Total 847.20 100% 0.43%
Source: Bloomberg
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Overall this leads to a continuing value of $64.716bn.  
 
Table 22: Continuing Value Calculation 
Discounting Cash Flows 
After calculating the cash flows for the explicit forecast period until 2020 and estimating 
Monsanto’s continuing value, we can now discount and sum these cash flows based on the 
WACC of the respective discounting period. This leads to a company value of $61.703 million.  
 
Table 23: Monsanto Company Value 
Adding Bayer’s proposed synergies of $1.5, Monsanto can be valued at $63.2, which is above 
the current market value of the company of $53bn, however below the offer that Bayer has 
made. A reason for this might be that Bayer expects more growth in the seed business of 
Monsanto.  
Q2. Financing 
Risks of financing the deal and evaluation of Bayer proposal 
Risks: The major risk in financing the transaction is the size of the deal. Bayer needs to issue a 
substantial amount of equity in order to avoid a skyrocketing debt/EBITDA multiple and further 
downgrading by the credit rating agencies. This equity share is needed in order to receive the 




Continuing value 64,716.21      
Year Cash Flow Discounted Value
2016 2,440.77               2,332.17                 
2017 2,372.50               2,163.19                 
2018 2,664.56               2,316.25                 
2019 2,784.92               2,312.81                 
2020 2,711.77               2,138.12                 
2021+ 64,716.21             50,440.19               
Company Value (DCF) 61,702.74               
EV (Mkt Cap+Debt-Cash) 52,894.89               
Bayer Proposal ($128 per share) 65,234.68               
DCF incl. Synergies 63,202.74               
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bridge loan from the banks, as banks would otherwise fear that a refinancing of the bridge could 
run into severe problems. On the other hand, an equity increase of $19bn (~€18bn) would 
significantly dilute the current shareholder’s stake. And even though Bayer avoided the 
shareholder’s approval by not issuing more than $19bn, shareholders could still be dissatisfied. 
In case of a market crash, a slide of the Bayer share or a substantial appreciation of the USD 
versus the EUR, the company would have to issue even more new shares in order to raise the 
required amount of $19bn. This would consequently further dilute ownership and decrease the 
share price even more, thus contributing to the dissatisfaction of the shareholders.  
The debt issuance can be seen less risky and easier to manage due to the current low-interest-
rate environment as well as Bayer’s high creditworthiness. However, high debt also implies that 
future cash flows have to be used in order to repay debt rather than utilizing the money for 
further investments and thus growth. And, in addition, this transaction would be one of the 
largest debt issuances in the history of M&As.  
Evaluation: The bridge financing enables Bayer to close the gap between the need for cash and 
the liquidity event in which they will be able to issue the necessary debt and equity. Usually 
this should happen within the first 12 month and comes with certain warranties as e.g. a 
maximum debt-to-equity ratio.  
The equity financing is divided into two components: a rights issue as well as mandatory 
convertible bonds. A rights issue is generally more positively seen in the market than an 
accelerated book building (cash offer) where new shares are sold to investors at large which is 
additionally limited to 10% of share capital by German regulation (§ 208 AktG). Right offers 
protects existing shareholders from underpricing (DeMarzo & Berk, 2014).  
The mandatory convertible bonds will ultimately be converted into equity by dividing the 
aggregate investment amount by a conversion price in order to determine the number of shares. 
The use of this tool contributes to a flexibility for Bayer in the financing as it can be adapted to 
certain capital structure requirements at a given time and allows Bayer to tap an additional 
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investor pool (besides classic debt/equity). Another advantage is that if the conversion takes 
place within 3 years, the convertibles are seen as equity by rating agencies, while the company 
can still enjoy the tax shield of the interest rate payment. 
How to successfully issue the planned amount of equity? What is the max discount for the 
new shares to avoid a shareholder vote? 
As can be seen in the Bayer report annex (Exhibit 6), the company is allowed to increase its 
common stock by €530 million without prior consent of the shareholders. This amount divided 
by the company’s current capital stock (€2.117bn) yields 25%. Thus Bayer can increase its 
equity by 25% without any further hurdles. The nominal value of one share equals €2.56 
(€2.117bn / 826,947,808 shares outstanding). Dividing the capital stock raise (€2,117bn + €530 
million) by the nominal value of one share (€2.56) yields 207,029,919, which is the amount of 
new shares that Bayer can issue. The price for these shares can be assessed by dividing the 
equity fund needed ($19bn) by the amount of newly issued shares. This yields a price of $91.77, 
which equates a 12.6% discount to Bayer’s current share price of €100 and a EUR/USD 
exchange rate of 1.05.  
At this point it becomes obvious that Bayer could run into serious problems to issue the needed 
amount of equity. The success of the issuance depends on the share price that Bayer can offer 
the new shares ($91.77) and the respective exchange rate. If the Euro amount of $91.77 exceeds 
the current share price (currently €100, but with a lot of fluctuation since the acquisition 
announcement), investors won’t buy. This scenario could happen either if Bayer’s share value 
drops below $91.77 due to market fluctuations or if the exchange rate is unfavorable due to 
USD appreciation/EUR depreciation or most likely due to a combination of both. Bayer pledged 
to pay $19bn, but this money has to be raised in Euros as Bayer shares are denominated in this 
currency. In either case, Bayer could run the risk to not be able to issue the desired amount of 
equity unless with their shareholder’s approval.  
Bayer has to offer shares at a fair discount in order to be successful. The new shares have to be 
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issued at a discount to the market price, otherwise no one would buy. If the discount is big 
enough, all shares will be sold for sure. Generally, a discount close to the market price is 
desirable, as it is fairer to all investors irrespective of a subscription. However, if the price of 
the newly issued shares is too high, Bayer has to pay underwriting fees to the banks to make 
sure that all shares are sold. The smaller the discount to the market price, the more expensive 
the underwriting will be for the reason that banks will face a higher risk and thus need to be 
compensated. If Bayer wants to avoid shareholder consent, the maximum discount they can 
offer, given a constant exchange rate of 1.05 and a market value of €100 per Bayer share, equals 
12.6%.  
How will the share price be affected? 
This can be calculated by computing the theoretical ex-rights price which represents the deemed 
share value immediately after a rights issue. First, the price of the newly issued shares has to be 
assessed given an appropriate discount (e.g. 12.6% of €100 as of 01/03/17 equals €87). The 
number of new shares to issue can be calculated by the amount of equity needed (€18bn) divided 
by the new share price (yields 207,029,967 shares to be issued). The number of rights needed 
by an investor to purchase a new share can be obtained by dividing the current shares 
outstanding by the number of new shares that have to be issued (826,948,000/207,029,967 = 4). 
Next, the new market cap needs to be calculated by adding the equity raise to the former market 
cap (yields ~€100.8bn). Dividing the new market cap by the total amount of shares outstanding 
results in a new share price of €97.48 per Bayer share right after the new issue. The value of a 
right is thus €0.63 ((€100-€97.48)/4).  
Q3. Strategy 
Was the decision to acquire Monsanto right? Would there be alternatives?  
With respect to Bayer’s product portfolio, the acquisition makes a lot of sense. Bayer does not 
follow the same conglomerate approach as BASF. BASF can more easily deal with the 
diminishment in market relevance as only 9% of their overall sales come from agrochemicals, 
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while it is around 30% for Bayer. If BASF were to acquire Monsanto and all the other mergers 
would be accomplished, Bayer would most likely suffer from margin losses and decrease in 
profitability due to comparative disadvantage.  
Furthermore, Bayer will be able to generate more synergies than the competitor especially in 
the R&D area for genetically modified products. Due to its pharmaceutical orientation, Bayer 
has more know-how and capacities when it comes to research in this area. Moreover, unlike 
BASF, Bayer has already been engaged in the seed business. Even though BASF has 
collaborated with Monsanto previously, they have not yet risked the step to fully enter into the 
seed business, possibly due to image reasons.  
An alternative to Monsanto could be other smaller agrochemical companies such as NuFarm or 
KWS. However, as these companies are substantially smaller than Monsanto, this could put 
Bayer at risk that BASF acquires Monsanto.  
How will the competition most likely react?  
If all the deals will go through the antitrust regulations, there are most likely attractive 
divestments and thus investment opportunities for competition such as BASF. As mentioned 
above, Bayer will almost for sure have to divest the Stoneville Pedigreed Seed Company or the 
Delta & Pine Land Company. This is only one of many possible expansion opportunities for 
BASF. And since the merging companies are under pressure to sell, the price should also be 
quite attractive.  
Are there other factors that have not yet been considered? 
Other factors that could be considered in this deal are for example the risk management of 
foreign exchange fluctuations regarding the buying price of the target company. Bayer 
announced to pay $57bn for Monsanto’s equity. However, Bayer’s main operating currency is 
Euro. This means, with the USD appreciating, the buying price will be much more expensive 
in terms of EUR. Here, one could think of possible tools (i.e. derivatives) to hedge the foreign 
exchange risk.  
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Another factor is the cultural difference in leadership styles between Germans and Americans 
that is often neglected, however can play a major role for a successful acquisition. The cross-
border merger between Daimler and Chrysler in 1995 ended in a fiasco as cultural differences 
and organizational culture have both played their part.  
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